口服生物可用的SARS-CoV-2主要蛋白酶抑制剂表现出改善的亲和力和对突变的敏感性降低
Michael Westberg1,2,3, Yichi Su1,4, Xinzhi Zou5
1Department of Neurobiology, Stanford University, Stanford, CA 94305, USA.
Science translational medicine
|March 13, 2024
概括
由于新出现的耐药性,需要新的口服COVID-19药物. 研究人员开发了ML2006a4,它是SARS-CoV-2 Mpro的强有力的抑制剂,对抗耐药变种有希望.
科学领域:
- 病毒学 病毒学
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
背景情况:
- 目前的SARS-CoV-2 Mpro 抑制剂,如尼尔马特雷尔维尔,面临耐药性问题.
- 在SARS-CoV-2中出现的突变威胁到现有的COVID-19治疗的有效性.
- 开发下一代口服抗病毒药物对于持续的COVID-19管理至关重要.
研究的目的:
- 设计和开发针对SARS-CoV-2 Mpro.的新型口服生物可用抑制剂.
- 创建一种药物候选物,对现有和潜在的耐药性突变有效.
- 改善当前SARS-CoV-2抗病毒药物的疗效和药理动力学特性.
主要方法:
- 结构导向修改C型肝炎病毒蛋白酶抑制剂boceprevir (BPV).
- 开发ML2006a4,一种新型的皮科莫拉亲和抑制剂.
- 在临床前模型中评估抗病毒活性,口服药理动力学和治疗疗效.
- 对已知的耐药性转移突变的敏感性评估.
主要成果:
- ML2006a4显示了对SARS-CoV-2 Mpro.的皮科莫尔亲和力.
- 该抑制剂表现出强大的抗病毒活性和良好的口服药理学.
- ML2006a4显示治疗效果与涅马特里尔维尔相比或优于涅马特里尔维尔.
- 该化合物对赋予耐尼马特里尔维尔和恩西特里尔维尔耐药性的突变表现出降低的敏感性.
结论:
- 预测性药物设计可以克服SARS-CoV-2的抵抗机制.
- ML2006a4是一个有前途的第二代口腔治疗候选药物.
- 这种方法扩大了对不断演变的冠状病毒变种的未来治疗选择.
更多相关视频
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
2.7K
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.0K
相关概念视频
Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
